Bahrain is suffering an 'epidemic' of young people using illegal performance enhancing drugs, according to fitness experts.
Health officials have confiscated hundreds of shipments of steroids, body enhancing substances and
US health regulators expanded the approval of Roche Holding's breast cancer drug Perjeta and will now allow its use to help shrink tumors prior to surgery, the Food and Drug Administration said on Monday.
The decision followed
US health regulators have strengthened the warnings on two blood cancer drugs to reflect the risk that they may reactivate the hepatitis B virus in patients previously infected with the disease.
The warnings affect GlaxoSmithKline
The hunt for new heart drugs is losing momentum as resources are switched to other areas, notably cancer research, where investors get a better bang for their buck.
Cardiologists fear the fight against heart di
US pharmaceutical investor Royalty Pharma on Friday raised its hostile bid for Irish drug firm Elan to a potential $8 billion, the third increase in five months.
A majority of Elan shareholders have held off tendering their shares
Michael Weitz was out of options. The Californian had endured chemotherapy, radiation and surgery but his lung cancer still spread to his bones and brain.
With time running out, the emergency room physician entered a Phase I study
US regulators approved 39 new drugs in 2012, the most in 16 years, suggesting that pharmaceutical makers are poised for growth after losing billions of dollars in recent years to generic drug makers because of patent expirations.
In February 2008, Mexican authorities told the CEO of HSBC Holdings' Mexico unit that a local drug lord referred to the bank as the "place to launder money," US prosecutors said on Tuesday, as they announced a rec
A Chinese herb called Ginkgo biloba billed by some as a potential over-the-counter wonder drug that boosts mental dexterity and sharpens the memory has been found to do nothing to prevent the onset of Alzheimer's disease.
Roche Holding's cancer drug Avastin has been rejected by Britain's healthcare cost agency as a first-line treatment for advanced breast cancer, the latest in a series of setbacks for this medicine.
The National Institute for Health and Cli